Cancer Center Trials: Reasons for Low Accrual Rates at One Academic Institution Vs. The Community Setting
Information source: University of New Mexico
Information obtained from ClinicalTrials.gov on June 20, 2008
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Cancer
Phase: N/A
Status: Completed
Sponsored by: University of New Mexico Official(s) and/or principal investigator(s):
Claire Verschraegen, MD, Principal Investigator, Affiliation: University of New Mexico
Summary
1. To identify reasons for low patient recruitment numbers to clinical trials in a cancer
research center setting (and a community setting) in order to attempt to increase
accrual rates.
2. To review the screening sheet for women who considered participating in the study of
Tamoxifen and Raloxifene (STAR) for the prevention of breast cancer in high risk women
through the University of New Mexico in Albuquerque from 1999 through 2004
Clinical Details
Official title: Cancer Center Trials: Reasons for Low Accrual Rates at One Academic Institution Vs. The Community Setting
Study design: Ecologic or Community, Retrospective
Detailed description:
Objective 1: All new cancer patients seen for a four month period at the University of New
Mexico Cancer Research and Treatment Center (UNM CRTC) (academic population) and for a six
month-period at the New Mexico Cancer Care Alliance (NMCCA) (community setting). A careful
screening log will be kept during this period with the research nurses cooperation in
documenting 1) whether patients seen were accrued to a clinical trial, 2) what available
trials the patient might possibly be eligible for, and 3) the reason for not registering on
to a clinical trial.
Objective 2: To compare the responses to questions on the entry forms of those women who were
eligible and declined participation to those who participated by Hispanic versus non-Hispanic
ethnicity, we will access, copy, and analyze all the risk assessment profiles otherwise known
as entry or eligibility forms completed by women who considered participating in the study of
Tamoxifen and Raloxifene (STAR). Patterns of eligibility criteria and risk assessment will be
described by ethnicity of women considered for entry into this chemopreventive randomized
trial without the use of personal identifying data in accordance with the Health Insurance
Portability Accountability Act of 1996 to maintain patient confidentiality
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Women who considered participating in the study of Tamoxifen and Raloxifene (STAR) for
the prevention of breast cancer in high risk women through the University of New
Mexico in Albuquerque from 1999 through 2004
Exclusion Criteria:
- Not specified.
Locations and Contacts
University of New Mexico, Albuquerque, New Mexico 87114, United States
Additional Information
Starting date: January 2005
Ending date: June 2007
Last updated: April 28, 2008
|
